Get the right diagnosis the first time
Patients with infectious illnesses often have signs and symptoms that are indicative of a disease, but that isn't specific enough to clinically distinguish what makes them ill. These patients are frequently given broad treatment, heavy monitoring and possibly unnecessary interventions. This puts a burden on healthcare systems, clinical labs and clinicians, and means patients aren't getting the best care possible.
We’re committed to helping healthcare workers like you navigate the challenges of diagnosing infectious diseases. That’s why we’ve developed an easy-to-use, automated diagnostic testing system that can help eliminate the guesswork and make your job easier. Our tests use multiplex PCR technology – also known as syndromic testing – that can quickly survey many different pathogens in a single patient sample. With syndromic testing, you get the answers you need, when you need them. And your patients get better care, faster.
We’re committed to helping healthcare workers like you navigate the challenges of diagnosing infectious diseases. That’s why we’ve developed an easy-to-use, automated diagnostic testing system that can help eliminate the guesswork and make your job easier. Our tests use multiplex PCR technology – also known as syndromic testing – that can quickly survey many different pathogens in a single patient sample. With syndromic testing, you get the answers you need, when you need them. And your patients get better care, faster.
Latest insights – webinars, stories and more
-
Syndromic testing webinar hubWatch our most recent webinars to learn how experts have incorporated syndromic testing into their diagnostic approach. Plus, get the latest insights on molecular diagnostics for infectious diseases. -
Can your testing platform talk to you?The QIAstat-Dx Analyzer can, with push notifications sent through the QIAsphere app. The app works in harmony with your local network to help you maximize productivity – learn more in our connectivity guide. -
Q&A with the expertsHow will syndromic testing impact diagnostics going forward? Find out in this Q&A article. -
A small revolution in a Parisian hospitalFor Dr. Celestin Alexis Agbessi and Dr. Benoît Visseaux of Bichat-Claude Bernard hospital in Paris, clear diagnoses are crucial. Learn why Dr. Visseaux calls syndromic testing “nothing less than a small revolution.” -
A simple syndromic workflowSee how quick and intuitive syndromic testing can be. Use this interactive demo to try out the QIAstat-Dx Analyzer for yourself.
This respiratory season will be uniquely challenging
Visit our respiratory resources hub to learn how we can support you.
Voices from the field – how medical professionals are using syndromic diagnostics
“It changed our perception, our prescription habits, and it will change the way we work in the future. In the end, we gain money for both the community and the patients. That is really a big step forward.”
Celestin Alexis Agbessi, M.D., Bichat-Claude Bernard Hospital, Paris
“It’s hugely beneficial to be able to test for that wide range of pathogens. Ruling out COVID is helpful, but so is the chance to correctly identify other illnesses so physicians can treat the patients and their symptoms appropriately.”
Michelle Volk, CEO and president of Great Lakes Labs, Indiana, USA
“Our value to our patients and to our provider community has increased by bringing the QIAstat-Dx in-house.”
Joshua Arant, Founder and Chief Operations Officer, Mako Medical
Why choose syndromic testing as a diagnostic tool?
-
Laboratory benefits
- Easy to set up a test, with less than one minute hands-on time
- Increased analytical sensitivity1,2,3 versus traditional methods
- Ct data and amplification curves visible for detected pathogens
-
Patient benefits
- Comprehensive results for more than 20 pathogens with faster turnaround times4 can support faster clinical decision making
- Associated with reduced hospital length of stay5, improved patient management6 and better outcomes7
-
Antimicrobial stewardship benefits
- Comprehensive results allow causative pathogens to be identified quickly
- Supports the use of a targeted therapeutic approach to reduce inappropriate antibiotic use8 and antibiotic duration8
-
Healthcare cost benefits
- A reduction in the need for follow-up testing, shorter hospital stays and more efficient testing can reduce overall healthcare costs9
New to rapid diagnostics with syndromic testing?
Find the information you need and learn how to incorporate syndromic testing into your diagnostic strategy.
Featured – resources for infectious disease diagnostics
-
Adopting a new approach to serve the community during COVID-19When COVID-19 struck in Indiana, USA, CEO and president of Great Lakes Labs, Michelle Volk, knew that she wanted to help. Learn how she adopted syndromic testing to help provide fast answers and peace of mind to her community. -
Top 3 considerations during respiratory seasonAs we enter respiratory season, one topic drawing attention is co-infections between influenza-like illnesses and COVID-19. -
COVID-19 solutions and resourcesLearn more about how QIAGEN solutions can be used in the fight against COVID-19, or get in touch to let us know how we can support your lab.
icon-cta-contact
Have a question about multiplex panel testing?
Get in touch with us today.
References
- Yalamanchili H, et al. (2018) Gastroenterol Hepatol, 14(11):646-652
- Binnicker M. Multiplex. (2015) J. Clin Microbiology, 53(12):3723-3728
- Macfarlane-Smith L, et al. (2018) Gastrointestinal Infections, 34(1):19-2
- Echavarria M, et al. (2018) J Clin Virol, 108:90–95
- Beal S G, et al. (2018) J Clin Microbiol, 18;56(1)
- Bouzid D, et al. (2020) J Hospital Infection, 337-338
- Iroh Tam PY, et al. (2017) Children (Basel), 4(1)
- Zhu et al. (2018) Clin Pediatr, 58(2): 185-190
- Martinez RM, et al. (2016) Clinical Virology Symposium, Poster #C-368
The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
- This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner